<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142103</url>
  </required_header>
  <id_info>
    <org_study_id>B1211001</org_study_id>
    <secondary_id>CPG10101-003</secondary_id>
    <nct_id>NCT00142103</nct_id>
  </id_info>
  <brief_title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects</brief_title>
  <official_title>CPG10101 Combination Therapy For The Treatment Of Hepatitis C: A Phase 1b Open Label Randomized Trial Of CPG10101 Alone, With Interferon, Ribavirin, Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus (HCV) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To characterize the tolerability profile of subcutaneous (SC) CPG 10101 alone, with
           pegylated interferon, ribavirin or both pegylated interferon and ribavirin when
           administered weekly for twelve weeks in relapsed HCV positive subjects.

        2. To assess the effect of subcutaneous (SC) CPG 10101 alone, with pegylated interferon,
           ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus (HCV)
           RNA concentrations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, vital signs, clinical and laboratory parameters, physical exam, ECG</measure>
    <time_frame>16wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum HCV RNA concentrations: Serum HCV concentrations over time to baseline</measure>
    <time_frame>12wks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Hepatitis, Chronic Active</condition>
  <arm_group>
    <arm_group_label>CPG10101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPG10101 + pegylated interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPG10101 + ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPG10101 + pegylated interferon + ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated inteferon + ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPG10101 + pegylated interferon + ribavirin (rollover)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG10101</intervention_name>
    <description>CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks</description>
    <arm_group_label>CPG10101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG10101</intervention_name>
    <description>CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks</description>
    <arm_group_label>CPG10101 + pegylated interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG10101</intervention_name>
    <description>CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks</description>
    <arm_group_label>CPG10101 + ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG10101</intervention_name>
    <description>CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks</description>
    <arm_group_label>CPG10101 + pegylated interferon + ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks</description>
    <arm_group_label>Pegylated inteferon + ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG10101</intervention_name>
    <description>CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks</description>
    <arm_group_label>CPG10101 + pegylated interferon + ribavirin (rollover)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HCV positive subjects documented by serum HCV RNA concentration greater than 1000 IU/mL
        within 21 days of first study treatment.

        Receipt of adequate pegylated IFN plus RVN based therapy for a minimum of 24 weeks
        (pegylated interferon doses of &gt; 180 μg weekly or &gt; 1.0 μg/kg pegylated interferon weekly
        and at least 800 mg RVN daily) resulting in undetectable HCV RNA concentrations while on
        treatment with subsequent relapse (HCV RNA concentration detected) within six months of
        stopping therapy.

        HCV genotype 1. Adults, 18 + years old. Written Informed Consent. Liver biopsy documenting
        changes of Hepatitis C within 5 years of the first dose of study drug.

        Adequate bone marrow, liver, and renal function demonstrated by:

          -  hemoglobin &gt; 12 g/dL for females and &gt; 13 g/dL for males

          -  WBC &gt; 3,000/mm3

          -  Neutrophils &gt; 1,500/mm3

          -  Platelets &gt; 80,000/mm3

          -  Total bilirubin &lt; 1.6 mg/dL.

          -  Direct bilirubin &lt; 1.5 upper limit of normal. If indirect bilirubin is elevated,
             Gilbert's disease must be documented in chart and substantiated.

          -  Albumin within normal limits (per central laboratory)

          -  Serum creatinine &lt; upper limit normal per central laboratory or calculated creatinine
             clearance &gt; 100 mL/min (by Cockroft-Gault formula).

        Negative pregnancy test in women of child bearing potential Females of childbearing
        potential and males who have partners of childbearing potential must use two forms of
        effective contraception during treatment and during the 6 months after treatment has been
        concluded.

        Exclusion Criteria:

        Treatment with IFN based therapies and/or antiviral therapies within 90 days of the first
        dose of study drug.

        Child-Pugh Class B or C. History of psychiatric conditions including, but not limited to,
        psychosis, suicidal ideations, or major depression. Subjects with mild to moderate
        depression in the past who have a normal to mild Beck Depression Inventory Score and no
        prior history of suicidal gestures or attempts may be enrolled if, in the Investigator's
        opinion, they are suitable for treatment.

        Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure; myocardial
        infarction within the past 6 months; unstable angina; coronary angioplasty within the past
        6 months; uncontrolled atrial or ventricular cardiac arrhythmias).

        History of immunodeficiency, autoimmune disease, autoimmune hepatitis, allogeneic
        transplant, or pre-existing autoimmune or antibody-mediated disease including but not
        limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis,
        Sjogren's syndrome, autoimmune thrombocytopenia.

        Other serious medical conditions including, but not limited to:

          -  HIV-1,

          -  Hepatitis B (positive HBsAg),

          -  Cancer,

          -  Pregnant, partners of pregnant women, or nursing women, and/or

          -  Alcohol or drug misuse within 90 days of screening Use of immunosuppressive doses of
             steroids or any antimetabolite therapies within 3 months of entry into the study
             (inhaled and topical corticosteroids are permitted).

        Receipt of any vaccine or immunoglobulin within 30 days before the first dose of study drug
        Prior administration of oligodeoxynucleotides (including study medication CPG 10101),
        ribozymes, or any known allergy to CPG 10101, interferon, ribavirin or their excipients
        Receipt of any investigational drug therapy within 30 days before the first dose of study
        drug Any other condition that, in the opinion of the Investigator, may compromise the
        safety or compliance of the subject or would preclude the subject from successful
        completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305-2071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1211001&amp;StudyName=CPG10101%20Combination%20Therapy%20For%20The%20Treatment%20Of%20Hepatitis%20C%20In%20Relapsed%20HCV%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Hepatitis c virus</keyword>
  <keyword>HCV</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

